Summary

Musculoskeletal Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Musculoskeletal Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Musculoskeletal Pain, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...

Summary

GlobalData's clinical trial report, “Musculoskeletal Pain Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Musculoskeletal Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Musculoskeletal Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter stra...

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) Overview 6
Therapeutics Development 7
Pipeline Products for Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Overview 7
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics under Development by Companies 8
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Products under Development by Companies 11
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Companies Involved in Therapeutics Development 12
AndroScience Corp 12
Armgo Pharma Inc 13
Novartis AG 14
Vybion Inc 15
Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19 $2,000.00 ]]> Fri, 07 Apr 2017 13:51:23 +0000 https://www.leadingmarketresearch.com/epiomic-epidemiology-series-muscular-dystrophies-forecast-in-12-major-mark Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Muscular Dystrophies in 12 Major Markets The muscular dystrophies (MD) are a group of more than 30 genetic diseases characterized by progressive muscle weakness and degeneration leading to reduced mobility. The specific types of MD are classified based on severity, pattern of inheritance, age at onset, affected muscle groups or other organs, specific genetic mutation and gender affected. Different forms of MD can manifest at different stages of life, from infancy to late adulthood. The different types of MD can affect different organs and systems such as the brain, heart, blood vessels, muscles of respiration and gastrointestinal tract. This report provides the current prevalent population for Muscular Dystrophies across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific v...

Summary

Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2016’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical ...

Summary

GlobalData's clinical trial report, “Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2016" provides an overview of Spinal Muscular Atrophy (SMA) clinical trials scenario. This report provides top line data relating to the clinical trials on Spinal Muscular Atrophy (SMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effect...

VPGMarketResearch.com's new report is a strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic hospital, commercial and point-of-care/POC markets during the next five years. The report explores future trends in the US market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.